ALBANY, New York: Migraine is a common disease that afflicts almost 14.7pc of the world population. As per the World Health Organization, its prevalence is estimated to be 12pc among general population. It is found that females are 2 to 3 times more susceptible to the chronic condition.
With the rise of the female population and the increase in overall population, particularly in developing nations, the global migraine drugs market will be boosted majorly in the next couple of years.

A research study by Transparency Market Research states that the global migraine drugs market was worth US$2.72 bn in 2016. The report forecasts the market to attain a value of US$3.72 bn by 2025 by registering a tepid CAGR of 3.5% from 2017 and 2025.

Serving to hinder the market, on the other hand, is the easy availability of generics and over reliance on over the counter (OTC) pain killers and other drugs in emerging and under developed markets. The lead analyst of the TMR report observes, "Companies that manufacture and sell migraine drugs that exhibit a high safety and efficacy profile are expected to gain a competitive edge over their peers."

The global market for migraine drugs can be divided based on the types of treatments into abortive treatment and prophylactic treatment. The abortive treatment can be divided further into triptans, ergot alkoids, etc. The prophylactic treatment segment too can be segmented again into botulinum toxin, topiramate, etc. At present, the segment of abortive treatment, powered mainly by triptans, leads the market with a higher share.

(Posted on 09 October 2017, 1670214045 3O225O221O130)